Your browser doesn't support javascript.
loading
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau, Moritz; Thus, Yvonne J; Robrecht, Sandra; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie; Dubois, Julie; von Tresckow, Julia; Patz, Michaela; Gregor, Michael; Thornton, Patrick; Staber, Philipp B; Tadmor, Tamar; Levin, Mark-David; da Cunha-Bang, Caspar; Schneider, Christof; Poulsen, Christian Bjoern; Illmer, Thomas; Schöttker, Björn; Janssens, Ann; Christiansen, Ilse; Nösslinger, Thomas; Baumann, Michael; Hebart, Holger; Gaska, Tobias; Regelink, Josien C; Dompeling, Ellen C; Lindström, Vesa; Juliusson, Gunnar; Widmer, Anouk; Goede, Jeroen; Goldschmidt, Neta; Simon, Florian; De Silva, Nisha; Fink, Anna-Maria; Fischer, Kirsten; Wendtner, Clemens-Martin; Ritgen, Matthias; Brüggemann, Monika; Tausch, Eugen; Spaargaren, Marcel; Eldering, Eric; Stilgenbauer, Stephan; Niemann, Carsten U; Hallek, Michael; Eichhorst, Barbara; Kreuzer, Karl-Anton; Kater, Arnon P.
Afiliação
  • Fürstenau M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Thus YJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Robrecht S; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Mellink CHM; Genome Diagnostics Laboratory, Section Cytogenetics, Department of Human Genetics, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • van der Kevie-Kersemaekers AM; Genome Diagnostics Laboratory, Section Cytogenetics, Department of Human Genetics, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • von Tresckow J; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Patz M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Gregor M; Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
  • Thornton P; Swiss Group for Clinical Cancer Research, Berne, Switzerland.
  • Staber PB; Department of Haematology, Beaumont Hospital, RCSI University of Medicine and Health Sciences, Cancer Trials Ireland, Dublin, Ireland.
  • Tadmor T; Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Levin MD; Hematology, Bnai-Zion Medical Center, Haifa, Israel.
  • da Cunha-Bang C; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Schneider C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Poulsen CB; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Illmer T; Department of Hematology, Zealand University Hospital, Roskilde, Roskilde, Denmark.
  • Schöttker B; BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany.
  • Janssens A; Hämatologisch-onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.
  • Christiansen I; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
  • Nösslinger T; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
  • Baumann M; Department of Internal Medicine III, Hanusch Hospital, Vienna, Austria.
  • Hebart H; Swiss Group for Clinical Cancer Research, Berne, Switzerland.
  • Gaska T; Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Regelink JC; Department of Oncology, Stauferklinikum, Mutlangen, Germany.
  • Dompeling EC; Hematology and Oncology, Brüderkrankenhaus, Paderborn, Germany.
  • Lindström V; Department of Haematology, Meander Medisch Centrum, Amersfoort, The Netherlands.
  • Juliusson G; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands.
  • Widmer A; Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Goede J; Department of Hematology, Skåne University Hospital, Lund, Sweden.
  • Goldschmidt N; Swiss Group for Clinical Cancer Research, Berne, Switzerland.
  • Simon F; Department of Medical Oncology and Haematology, Universitätsspital Zürich, Zürich, Switzerland.
  • De Silva N; Swiss Group for Clinical Cancer Research, Berne, Switzerland.
  • Fink AM; Clinic for Medical Oncology and Hematology, Cantonal Hospital of Winterthur, Winterthur, Switzerland.
  • Fischer K; Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.
  • Wendtner CM; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Ritgen M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Brüggemann M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Tausch E; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
  • Spaargaren M; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Munich Clinic Schwabing, Munich, Germany.
  • Eldering E; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.
  • Stilgenbauer S; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.
  • Niemann CU; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Hallek M; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Eichhorst B; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Kreuzer KA; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Kater AP; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Blood ; 142(5): 446-459, 2023 08 03.
Article em En | MEDLINE | ID: mdl-37172204
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha